Stem Cell Factor (SCF/KITLG): KIT Receptor Tyrosine Kinase Ligand Governing HSC Maintenance, Mast Cell Biology, and Oncogenic Signaling in GIST and Mastocytosis Research

# Stem Cell Factor (SCF/KITLG): KIT Receptor Tyrosine Kinase Ligand Governing HSC Maintenance, Mast Cell Biology, and Oncogenic Signaling in GIST and Mastocytosis Research

Discovery, Genetics, and Molecular Structure

Stem cell factor (SCF) was simultaneously discovered in 1990 by two groups using complementary approaches. Williams and colleagues purified and cloned the factor from BRL-3A rat liver cell conditioned medium based on its ability to support hematopoietic progenitor growth in combination with erythropoietin (Williams et al., 1990, PMID: 2155230), while Zsebo and colleagues identified the same factor as the product of the mouse Steel (Sl) locus — mutations in which had caused a pleiotropic syndrome of anemia, mast cell deficiency, sterility, and white spotting known since the 1940s (Zsebo et al., 1990, PMID: 2155229). The parallel identification of SCF as the Steel locus product (hence alternative name "Steel factor") with the c-Kit proto-oncogene product (KIT/CD117) as its receptor — whose mutations cause the White spotting (W) locus syndrome with essentially identical phenotype — established one of the best-validated ligand-receptor pairs in biology: two distinct genetic loci encoding a ligand and receptor whose loss produces the same phenotype.

The human KITLG gene maps to chromosome 12q22 and encodes a 273-amino acid type I transmembrane precursor. Alternative splicing of exon 6 generates two primary membrane-bound isoforms:

KL-1 (SCF-248): Retains exon 6 (encoding a proteolytic cleavage site in the extracellular domain juxtamembrane region). KL-1 is shed from the cell surface by metalloprotease (ADAM10/17) cleavage at Ala165, generating a soluble ~18.5 kDa form that circulates in plasma at concentrations of 1–3 ng/mL. N-glycosylation at Asn65, Asn72, Asn109, and Asn120 contributes ~10 kDa, bringing the total soluble molecular weight to ~28–32 kDa.

KL-2 (SCF-220): Lacks exon 6 encoding the KL-1 proteolytic site; KL-2 is predominantly membrane-retained, shedding poorly. KL-2 membrane-bound form signals through KIT with distinct kinetics — sustained receptor activation (vs. more transient signaling from soluble SCF) — and is critical for some biological contexts, particularly mast cell survival in tissues and HSC niche retention. Steel-Dickie (Sl^d) mice expressing only a membrane-deleted SCF isoform have severe anemia and mast cell deficiency despite abundant mRNA, definitively establishing that soluble SCF alone cannot rescue all KL-2-dependent functions.

Mature soluble SCF adopts a non-covalent homodimer structure; each monomer contains a four-helical bundle (helices A–D) with two intrachain disulfide bonds (Cys4–Cys89; Cys43–Cys138) essential for receptor binding. SCF Site I (helices A and C) contacts KIT domain D2-D3, and SCF Site II binds a second KIT molecule, driving 2:2 SCF:KIT dimerization for receptor activation.

Primary sources of SCF: bone marrow stromal fibroblasts, endothelial cells, Sertoli cells (testis), keratinocytes, astrocytes, and liver sinusoidal cells constitutively produce membrane-bound SCF; hepatocytes are a major source of soluble circulating SCF.

KIT Receptor: Architecture, Dimerization, and Signal Transduction

KIT (CD117) is a class III receptor tyrosine kinase encoded by KIT on chromosome 4q12, in a cluster with PDGFRA and PDGFRB. The 976-amino acid type I transmembrane protein consists of:

Extracellular domain (D1–D5, five Ig-like domains): D1–D3 constitute the ligand-binding region (SCF contacts D2–D3); D4 mediates KIT:KIT homotypic contacts that stabilize the activated dimer; D5 directly couples to the transmembrane helix. D4 contains a salt bridge (Asp419–Arg420) interaction across the D4-D4 interface that is critical for full receptor activation — mutations at D4 interface residues suppress signaling without preventing ligand binding.

Transmembrane helix and juxtamembrane domain: The juxtamembrane (JM) domain inserts into the kinase domain activation loop cleft in the autoinhibited state, stabilizing the inactive conformation. Mutations in the JM domain (exon 11: V559D, W557R, del559-560) are the most common KIT mutations in GIST (~70% of all KIT-mutant GIST) and disrupt autoinhibition, leading to constitutive kinase activity without ligand.

Split kinase domain (KD1: kinase insert domain, KD2: catalytic domain): The kinase insert domain (encoded by exon 11) is unique to class III RTKs and serves as a regulatory module. The D816V substitution in the KD2 activation loop (exon 17) is the dominant activating mutation in systemic mastocytosis (>90% of SM cases), causing constitutive kinase activity in a conformation that is imatinib-insensitive.

SCF binding → KIT dimerization → trans-autophosphorylation activates multiple downstream pathways:

PI3K/AKT/mTOR (pY719 in KIT kinase insert domain): The dominant survival and proliferation signal. p85 PI3K binds phospho-Y719; downstream AKT phosphorylates FOXO3a (anti-apoptotic), MDM2 (p53 degradation), TSC2 (mTORC1 activation). In GIST, PI3K/AKT is constitutively active via gain-of-function KIT mutations and is the key resistance pathway when KIT is suppressed.

RAS/MAPK/ERK (GRB2/SOS/RAS→RAF→MEK→ERK): Proliferative signal activated by KIT pY703/pY936 → GRB2 adaptor. Critical for mast cell proliferation and HSC expansion; ERK1/2 targets include ELK1, RSK, and MNK1.

JAK/STAT signaling: KIT activates JAK1/2 and STAT1/3/5; STAT5 is particularly important for SCF-driven megakaryocyte and mast cell responses.

PLCγ1 (pY936 in kinase insert domain): Generates IP3 (Ca²⁺ mobilization) and DAG (PKC activation), contributing to mast cell degranulation/activation responses.

SRC family kinases (LYN, FYN): Activated by KIT via multiple mechanisms; contribute to cytoskeletal reorganization, cell migration, and mast cell IgE-independent activation.

SHP2/GRB2: Adaptor function; SHP2 also provides negative feedback phosphatase activity.

CBL E3 ubiquitin ligase (binds pY1001/Y1021): Principal negative regulator; ubiquitinates KIT for internalization and proteasomal degradation. CBL loss-of-function mutations in AML/MDS maintain KIT surface expression and potentiate SCF/KIT signaling.

Biological Roles of SCF/KIT Signaling

Hematopoietic Stem Cell Maintenance and Migration

KIT is expressed on virtually all HSCs, multipotent progenitors, and lineage-committed progenitors until late-stage differentiation. SCF/KIT signaling is required for:

• •HSC quiescence maintenance in the endosteal niche (cooperation with CXCL12/CXCR4 and angiopoietin-1/Tie2)
• •HSC survival (PI3K/AKT-BCL-XL) and symmetric/asymmetric division balance
• •HSC migration from fetal liver to bone marrow during development
• •Emergency hematopoiesis — SCF cooperates with THPO and EPO to drive rapid progenitor expansion

W/W^v mice (KIT hypomorphic) and Sl/Sl^d mice (SCF partial loss) both show macrocytic anemia, mast cell absence, and melanocyte defects. However, unlike Thpo/Mpl knockout mice, W/W^v mice retain residual HSC numbers despite functional impairment, indicating that KIT/SCF are required for optimal but not absolute HSC survival (unlike THPO/MPL).

Mast Cell Development and Tissue Survival

Mast cells are uniquely dependent on SCF/KIT signaling for survival throughout their lifespan — unlike most hematopoietic cells that lose KIT expression as they mature, mast cells retain high KIT surface expression (>50,000 receptors/cell) permanently. Tissue mast cells require constitutive low-level SCF from local fibroblasts and epithelial cells for survival; withdrawal leads to apoptosis within 48 hours. SCF cooperates with IL-3 for mast cell proliferation in early marrow stages, but KIT remains the dominant survival signal in peripheral tissues.

This KIT dependence makes mast cells exquisitely sensitive to KIT inhibition — imatinib depletes tissue mast cells as an on-target pharmacological effect, relevant to its use in cutaneous mastocytosis and IgE-mediated conditions.

Melanocyte Development (c-Kit/SCF and Skin Pigmentation)

Melanocyte progenitors (melanoblasts) derived from neural crest cells require KIT for survival and migration during embryonic development from the dorsolateral migration pathway to the skin. W locus mice lack melanocytes → white spotting. In humans, loss-of-function KIT variants cause piebaldism (autosomal dominant white forelock + depigmented patches); gain-of-function KIT mutations in uveal melanoma promote proliferation, and KIT amplification/mutation is found in ~15–20% of acral/mucosal melanoma but rarely in cutaneous sun-exposed melanoma (reflecting different melanocyte biology at non-UV-exposed sites).

Germ Cell Development and Fertility

Primordial germ cells (PGCs) require SCF/KIT signaling for migration from the yolk sac along the hindgut to the genital ridges, and for survival/proliferation in the developing gonad. Sl and W mutant mice are infertile — Sertoli cell-derived SCF is required for spermatogonial stem cell (SSC) self-renewal and early differentiation. This germ cell dependence is exploited in research to selectively ablate SSCs using anti-KIT immunotoxins.

Interstitial Cells of Cajal (Gastrointestinal Pacemakers)

Interstitial cells of Cajal (ICC) are the pacemaker cells of gastrointestinal smooth muscle. ICC require SCF/KIT for development and maintenance — W/W^v mice lack ICC and have severely impaired GI motility. ICC are the normal cell of origin for gastrointestinal stromal tumors (GIST), directly linking ICC KIT dependence to the oncogenic role of gain-of-function KIT mutations in GIST.

KIT in Oncology: GIST and Systemic Mastocytosis

Gastrointestinal Stromal Tumors (GIST)

• •Exon 11 (JM domain): Most common (~70% of KIT-mutant GIST); deletions (del557-558), point mutations (V559D, W557R), insertions; disrupt JM autoinhibitory function; generally imatinib-sensitive
• •Exon 9 (D5 extracellular): ~10%; duplication Ala502-Tyr503; less imatinib-sensitive (respond better to sunitinib or higher imatinib dose)
• •Exon 13 (kinase domain): Rare (~1%); K642E; imatinib-resistant
• •Exon 17 (activation loop): Very rare in primary GIST (~1%); D816V-like; imatinib-resistant

Approximately 10–15% of GIST have PDGFRA mutations (chromosome 4q12 neighbor); ~5% are KIT/PDGFRA wild-type (NF1, SDH-deficient, BRAF-mutant).

Imatinib mesylate (Gleevec/Glivec), a BCR-ABL/KIT/PDGFRA inhibitor, revolutionized GIST treatment — Demetri et al. 2002 NEJM (PMID: 12181401) demonstrated response rates >50% in metastatic/unresectable GIST vs. <5% with chemotherapy. Imatinib binds the KIT ATP-binding cleft in the inactive (DFG-out) conformation; JM domain mutations facilitate this binding by eliminating JM autoinhibition. Sunitinib (multi-RTK inhibitor) is second-line; ripretinib (allosteric KIT "switch control" inhibitor) is approved for 4th+ line. Avapritinib targets KIT D816V and PDGFRA D842V specifically.

Systemic Mastocytosis

Systemic mastocytosis (SM) is characterized by clonal mast cell accumulation in bone marrow, liver, spleen, and skin driven by the KIT D816V point mutation (Asp816→Val in the activation loop, exon 17) in >90% of cases. D816V constitutively activates KIT in an "active" DFG-in conformation that is resistant to imatinib (which requires DFG-out binding) and sunitinib. D816V specifically activates STAT3/5 and PI3K more potently than wild-type KIT.

Avapritinib (BLU-285, Blueprint Medicines): a type I KIT inhibitor that binds the active (DFG-in) conformation; exquisitely selective for D816V over wild-type KIT. FDA approved November 2021 for advanced SM (indolent/smoldering SM approved June 2023 — PATHFINDER trial). Midostaurin (multi-kinase inhibitor including PKC-family) was FDA-approved in 2017 for advanced SM as the first approved therapy, prior to avapritinib.

Research Tools and Experimental Models

SCF/KIT in Immuno-Oncology and Non-Malignant Research

Allergy and mast cell biology: Tissue mast cells activated by IgE/FcεRI cross-linking or SCF co-stimulation degranulate (histamine, tryptase) and produce cytokines (IL-4, IL-13, TNF) and lipid mediators (PGD2, LTC4). KIT inhibition reduces mast cell burden and activation — rationale for imatinib in chronic urticaria, indolent SM, and idiopathic anaphylaxis research.

Melanoma: KIT is amplified or mutated in ~15% of acral/mucosal/uveal melanoma but not in typical cutaneous melanoma. Anti-KIT therapy (imatinib/dasatinib) has shown limited benefit in heavily pretreated KIT-altered acral melanoma, likely due to concurrent bypass pathways (NRAS, PI3K mutations).

Acute myeloid leukemia (AML): KIT D816V is found in core-binding factor AML (CBF-AML: t(8;21) and inv(16)) with ~25% incidence and confers adverse prognosis; standard therapy adding dasatinib or midostaurin to chemotherapy is under evaluation.

Ovarian failure and fertility preservation: KIT signaling on oocytes receiving SCF from granulosa cells is required for primordial follicle activation. Anti-KIT antibodies (ACK2) in mice suppress primordial follicle activation, providing a model for fertility preservation research in cancer patients receiving gonadotoxic chemotherapy.

Spermatogonial stem cell (SSC) transplantation: Depletion of recipient SSCs using busulfan or anti-KIT immunotoxins followed by donor SSC transplantation restores spermatogenesis in infertile male mice — a platform for fertility restoration research in gonadotoxic therapy survivors.

Current Research Frontiers

Next-generation KIT inhibitors in GIST: Resistance to imatinib typically involves secondary mutations in KIT exons 13/14/17/18 (kinase domain); ripretinib as a "switch-control" inhibitor that locks KIT in the inactive conformation regardless of activation loop mutation status addresses polyclonal resistance. Clinical trials combining ripretinib + binimetinib (MEK inhibitor) target MAPK bypass.

Avapritinib in indolent SM: Post-approval real-world data and biomarker analyses of D816V allele burden (digital droplet PCR) are defining response durability and remission criteria in non-advanced SM — where quality-of-life improvement is the primary endpoint.

SCF-based HSC expansion for transplantation: SCF + THPO + FLT3L + IL-6 cytokine cocktails (UM171, SR1 aryl hydrocarbon receptor antagonists as adjuncts) support HSC ex vivo expansion from cord blood, addressing the limiting factor of cell numbers for adult transplantation. UM171 has reached Phase II clinical study.

KIT as a CAR-T target: KIT expression on AML blasts and leukemic stem cells makes it a potential CAR-T target; however, on-target/off-tumor toxicity to normal hematopoiesis (KIT+ HSCs) requires careful dose/safety considerations. KIT-targeted immunotoxins are also in development for conditioning regimens in HSC transplantation, aiming to replace chemotherapy-based myeloablation.

Mast cell heterogeneity: Single-cell transcriptomics has defined at least 4–5 distinct mast cell subtypes in human tissue (connective tissue vs. mucosal; brain-resident vs. peritoneal), each with distinct KIT expression levels, mediator profiles, and SCF sensitivity. Understanding which subsets drive allergic disease vs. antimicrobial immunity has therapeutic implications for KIT inhibitor-based approaches in allergy.

Conclusion

The SCF/KIT axis illustrates how a single ligand-receptor pair can govern remarkably diverse biological processes — HSC maintenance, mast cell survival, melanocyte development, germ cell migration, and GI pacemaker cell identity — through context-dependent signaling outputs from the same JAK2/PI3K/MAPK/PLCγ core machinery. The convergent discovery of SCF as the Steel locus product and KIT as the White spotting locus gene in 1990 provided one of the most elegant genetic validations of a ligand-receptor pair in biology. Four decades later, gain-of-function KIT mutations in GIST and mastocytosis have made KIT one of the most clinically important kinase targets in oncology, with imatinib's success in GIST helping establish the paradigm of oncogene-directed targeted therapy that shaped modern precision medicine.

References

1. Williams DE, Eisenman J, Baird A, et al. Identification of a ligand for the c-kit proto-oncogene. Cell. 1990;63(1):167-174. PMID: 2155230

2. Zsebo KM, Williams DA, Geissler EN, et al. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell. 1990;63(1):213-224. PMID: 2155229

3. Huang E, Nocka K, Beier DR, et al. The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell. 1990;63(1):225-233. PMID: 2219131

4. Flanagan JG, Chan DC, Leder P. Transmembrane form of the kit ligand growth factor is determined by alternative splicing and is missing in the Sld mutant. Cell. 1991;64(5):1025-1035. PMID: 1705861

5. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577-580. PMID: 9438854

6. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472-480. PMID: 12181401

7. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113(23):5727-5736. PMID: 19363219

8. Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374(26):2530-2541. PMID: 27355533

9. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354(24):2531-2541. PMID: 16775234

10. Dewaele B, Wasag B, Cools J, et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res. 2008;14(18):5749-5758. PMID: 18794085

---

FOR RESEARCH USE ONLY. Not for human or veterinary use. Not for diagnostic or therapeutic applications. All biological activity data are derived from in vitro and preclinical studies; results may not predict human clinical outcomes. Information is provided for educational and research purposes only.